ArticleOncotarget2016
MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 115 citations in OpenAlex.
- 'Investigation of miRNAs That Affect the PI3K/AKT/mTOR Signaling Pathway in Endometrial Cancer'.Cell biochemistry and biophysics · 2025Article
- SNRK modulates mTOR-autophagy pathway for liver lipid homeostasis in MAFLD.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- PI3K/AKT pathway as a pivotal regulator of epithelial-mesenchymal transition in lung tumor cells.Cancer cell international · 2024Review
- Interaction between miR‑206 and lncRNA MALAT1 in regulating viability and invasion in hepatocellular carcinoma.Oncology letters · 2024Article
- LINC01060 knockdown inhibits osteosarcoma cell malignant behaviorsCancer biology & therapy · 2023Article
- Ion channel P2X7 receptor in the progression of cancer.Frontiers in oncology · 2023Review
- CircATIC Contributes to Multiple Myeloma Progression via miR-324-5p-Dependent Regulation of HGF.Biochemical genetics · 2022Article
- Angioregulatory microRNAs in breast cancerJournal of advanced research · 2022Review
- Novel Angiogenic Regulators and Anti-Angiogenesis Drugs Targeting Angiogenesis Signaling Pathways: Perspectives for Targeting Angiogenesis in Lung Cancer.Frontiers in oncology · 2022Review
- Review
- MicroRNA-206 suppresses growth and metastasis of breast cancer stem cells via blocking EVI-1-mediated CALR expression.PloS one · 2022Article
- MicroRNA-206 has a bright application prospect in the diagnosis of cases with oral cancer.Journal of cellular and molecular medicine · 2021Article
- MYOD1 inhibits avian adipocyte differentiation via miRNA-206/KLF4 axis.Journal of animal science and biotechnology · 2021Article
- Therapeutic potential of IBP as an autophagy inducer for treating lung cancer via blocking PAK1/Akt/mTOR signaling.Molecular therapy oncolytics · 2021Article
- Novel nanopolymer RNA therapeutics normalize human diabetic corneal wound healing and epithelial stem cells.Nanomedicine : nanotechnology, biology, and medicine · 2021Article
- miR-206 Inhibits Laryngeal Carcinoma Cell Multiplication, Migration, and Invasion.Journal of healthcare engineering · 2021Article
- MiRNAs as Anti-Angiogenic Adjuvant Therapy in Cancer: Synopsis and Potential.Frontiers in oncology · 2021Review
- Circulating microRNAs from serum exosomes as potential biomarkers in patients with spontaneous abortion.American journal of translational research · 2021Article
- Interferon-Induced Transmembrane Protein 3 Expression Upregulation Is Involved in Progression of Hepatocellular Carcinoma.BioMed research international · 2021Article
- Downregulation of miRNA‑328 promotes the angiogenesis of HUVECs by regulating the PIM1 and AKT/mTOR signaling pathway under high glucose and low serum condition.Molecular medicine reports · 2020Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MiR-206 is low expression in lung cancers and associated with cancer metastasis. However, the roles of miR-206 in epithelial-mesenchymal transition (EMT) and angiogenesis in lung cancer remain unknown. In this study, we find that hepatocyte growth factor (HGF) induces EMT, invasion and migration in A549 and 95D lung cancer cells, and these processes could be markedly inhibited by miR-206 overexpression. Moreover, we demonstrate that miR-206 directly targets c-Met and inhibits its downstream PI3k/Akt/mTOR signaling pathway. In contrast, miR-206 inhibitors promote the expression of c-Met and activate the PI3k/Akt/mTOR signaling, and this effect could be attenuated by the PI3K inhibitor. Moreover, c-Met overexpression assay further confirms the significant inhibitory effect of miR-206 on HGF-induced EMT, cell migration and invasion. Notably, we also find that miR-206 effectively inhibits HGF-induced tube formation and migration of human umbilical vein endothelial cells (HUVECs), and the mechanism is also related to inhibition of PI3k/Akt/mTOR signaling. Finally, we reveal the inhibitory effect of miR-206 on EMT and angiogenesis in xenograft tumor mice model. Taken together, miR-206 inhibits HGF-induced EMT and angiogenesis in lung cancer by suppressing c-Met/PI3k/Akt/mTOR signaling. Therefore, miR-206 might be a potential target for the therapeutic strategy against EMT and angiogenesis of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.